DXB.AX
Price:
$0.505
Market Cap:
$281.72M
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease. The company is headquartered in Fitzroy, Australia.[Read more]
Industry
Biotechnology
IPO Date
1989-07-31
Stock Exchange
ASX
Ticker
DXB.AX
According to Dimerix Limited’s latest financial reports and current stock price. The company's current ROE is -171.59%. This represents a change of -3.92% compared to the average of -178.58% of the last 4 quarters.
The mean historical ROE of Dimerix Limited over the last ten years is -133.26%. The current -171.59% ROE has changed 28.76% with respect to the historical average. Over the past ten years (40 quarters), DXB.AX's ROE was at its highest in in the March 2010 quarter at 0%. The ROE was at its lowest in in the December 2023 quarter at -388.66%.
Average
-133.26%
Median
-70.70%
Minimum
-433.89%
Maximum
-24.47%
Discovering the peaks and valleys of Dimerix Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 857.54%
Maximum Annual ROE = -24.47%
Minimum Annual Increase = -83.24%
Minimum Annual ROE = -433.89%
Year | ROE | Change |
---|---|---|
2024 | -93.89% | -59.44% |
2023 | -231.47% | 218.23% |
2022 | -72.74% | -83.24% |
2021 | -433.89% | 649.13% |
2020 | -57.92% | -15.66% |
2019 | -68.67% | 41.87% |
2018 | -48.41% | -27.61% |
2017 | -66.87% | -71.46% |
2016 | -234.31% | 857.54% |
2015 | -24.47% | -45.35% |
The current ROE of Dimerix Limited (DXB.AX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-132.70%
5-year avg
-177.98%
10-year avg
-133.26%
Dimerix Limited’s ROE is greater than Cynata Therapeutics Limited (-100.01%), greater than Oneview Healthcare PLC (-101.85%), greater than Proteomics International Laboratories Limited (-86.38%), greater than PharmAust Limited (-86.89%), greater than Minbos Resources Limited (-24.50%),
Company | ROE | Market cap |
---|---|---|
-100.01% | $51.81M | |
-101.85% | $216.15M | |
-86.38% | $90.39M | |
-86.89% | $111.93M | |
-24.50% | $53.35M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dimerix Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Dimerix Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Dimerix Limited's ROE?
How is the ROE calculated for Dimerix Limited (DXB.AX)?
What is the highest ROE for Dimerix Limited (DXB.AX)?
What is the 3-year average ROE for Dimerix Limited (DXB.AX)?
What is the 5-year average ROE for Dimerix Limited (DXB.AX)?
How does the current ROE for Dimerix Limited (DXB.AX) compare to its historical average?